Two Hundred Gastrointestinal Stromal Tumors
2000/01/01 by Ronald P. DeMatteo, Jonathan J. Lewis, Denis H. Y. Leung +5 · 29 citations
Medicine · #Gastrointestinal Tumor Research and Treatment #Minimally Invasive Surgical Techniques #Gastrointestinal disorders and treatments
paper · doi:10.1097/00000658-200001000-00008
Abstract
OBJECTIVE: To analyze the outcome of 200 patients with gastrointestinal stromal tumor (GIST) who were treated at a single institution and followed up prospectively. SUMMARY BACKGROUND DATA: A GIST is a visceral sarcoma that arises from the gastrointestinal tract. Surgical resection is the mainstay of treatment because adjuvant therapy is unproven. METHODS: Two hundred patients with malignant GIST were admitted and treated at Memorial Hospital during the past 16 years. Patient, tumor, and treatment variables were analyzed to identify patterns of tumor recurrence and factors that predict survival. RESULTS: Of the 200 patients, 46% had primary disease without metastasis, 47% had metastasis, and 7% had isolated local recurrence. In patients with primary disease who underwent complete resection of gross disease (n = 80), the 5-year actuarial survival rate was 54%, and survival was predicted by tumor size but not microscopic margins of resection. Recurrence of disease after resection was predominantly intraabdominal and involved the original tumor site, peritoneum, and liver. CONCLUSIONS: GISTs are uncommon sarcomas. Tumor size predicts disease-specific survival in patients with primary disease who undergo complete gross resection. Tumor recurrence tends to be intraabdominal. Investigational protocols are indicated to reduce the rate of recurrence after resection and to improve the outcome for patients with GIST.
Cited by
- Combined Surgical and Molecular Therapy
- Long-term Results of Adjuvant Imatinib Mesylate in Localized, High-Risk, Primary Gastrointestinal Stromal Tumor
- Diagnosis of gastrointestinal stromal tumors: A consensus approach
- Risk stratification of patients diagnosed with gastrointestinal stromal tumor
- The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. [europepmc]
- Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. [europepmc]
- A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. [europepmc]
- Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. [europepmc]
- Gastrointestinal stromal tumor. [europepmc]
- Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors. [europepmc]
- Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. [europepmc]
- Carbonic anhydrase II. A novel biomarker for gastrointestinal stromal tumors. [europepmc]
- NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. [europepmc]
- Laparoscopic versus open gastric resections for primary gastrointestinal stromal tumors (GISTs): a size-matched comparison. [europepmc]
- Gastrointestinal stromal tumors: correlation between symptoms at presentation, tumor location and prognostic factors in 47 consecutive patients. [europepmc]
- Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence. [europepmc]
- Management of gastric polyps: an endoscopy-based approach. [europepmc]
- Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial. [europepmc]
- Lessons learned from the study of 10,000 patients with soft tissue sarcoma. [europepmc]
- Epidemiology of gastrointestinal stromal tumors in the era of histology codes: results of a population-based study. [europepmc]
- Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial. [europepmc]
- Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. [europepmc]
- Gastrointestinal Stromal Tumors. [europepmc]
- Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. [europepmc]
- Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial. [europepmc]
- Outcome of 1000 Patients With Gastrointestinal Stromal Tumor (GIST) Treated by Surgery in the Pre- and Post-imatinib Eras. [europepmc]
- Prognostic Indicators for Gastrointestinal Stromal Tumors: A Review. [europepmc]
- Therapeutic Potential of PI3K/AKT/mTOR Pathway in Gastrointestinal Stromal Tumors: Rationale and Progress. [europepmc]
- New treatment strategies for advanced-stage gastrointestinal stromal tumours. [europepmc]
Related